Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial)

BACKGROUND: Treatment-free remission (TFR), the ability to maintain a molecular response (MR), occurs in approximately 50% of patients with chronic myelogenous leukemia (CML) treated with tyrosine kinase inhibitors (TKIs). METHODS: A multicenter phase 2 trial (Delightedly Overcome CML Expert Stop TK...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujisawa, Shin, Ueda, Yasunori, Usuki, Kensuke, Kobayashi, Hajime, Kondo, Eisei, Doki, Noriko, Nakao, Takafumi, Kanda, Yoshinobu, Kosugi, Nobuharu, Kosugi, Hiroshi, Kumagai, Takashi, Harada, Hiroshi, Shikami, Masato, Maeda, Yasuhiro, Sakura, Toru, Inokuchi, Koiti, Saito, Akio, Nawa, Yuichiro, Ogasawara, Masahiro, Nishida, Junji, Kondo, Takeshi, Yoshida, Chikashi, Kuroda, Hiroyuki, Tabe, Yoko, Maeda, Yoshinobu, Imajo, Kenji, Kojima, Kensuke, Morita, Satoshi, Komukai, Sho, Kawaguchi, Atsushi, Sakamoto, Junichi, Kimura, Shinya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438937/
https://www.ncbi.nlm.nih.gov/pubmed/30421023
http://dx.doi.org/10.1007/s10147-018-1368-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438937/
https://www.ncbi.nlm.nih.gov/pubmed/30421023
http://dx.doi.org/10.1007/s10147-018-1368-2

Ejemplares similares